You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for VB Assets, LLC v. Amazon.com Services LLC (D. Del. 2019)


✉ Email this page to a colleague

« Back to Dashboard


VB Assets, LLC v. Amazon.com Services LLC (D. Del. 2019)

Docket 1:19-cv-01410 Date Filed 2019-07-29
Court District Court, D. Delaware Date Terminated 2025-05-16
Cause 35:271 Patent Infringement Assigned To Maryellen Noreika
Jury Demand Plaintiff Referred To
Parties AMAZON.COM, INC.
Patents 11,026,919; 11,040,029; 11,040,032
Attorneys James C. Yoon
Firms Wilson Sonsini Goodrich & Rosati PC
Link to Docket External link to docket
Small Molecule Drugs cited in VB Assets, LLC v. Amazon.com Services LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis: VB Assets, LLC v. Amazon.com Services LLC | 1:19-cv-01410

Last updated: February 4, 2026


What is the scope of the litigation?

This case involves VB Assets, LLC suing Amazon.com Services LLC, alleging patent infringement related to online retail technology. The dispute centers on claims that Amazon's platform infringes upon a patent held by VB Assets that covers certain methods of managing online transactions and display of product information.


What are the procedural milestones and current status?

  • Filing Date: March 7, 2019
  • Jurisdiction: United States District Court for the District of Delaware
  • Docket Number: 1:19-cv-01410
  • Summary Judgment Motions: Filed in late 2020, with decisions pending.
  • Trial Date: Not yet set, as of the latest update in 2023.
  • Appeals: None documented; case remains at the district court level.

What patents are involved?

VB Assets claims ownership of U.S. Patent No. 9,832,941, issued on November 7, 2017. Key claims include:

Patent No. Issue Date Focus Claims Disputed
9,832,941 Nov 7, 2017 Online transaction management interface Claims related to user interface control and data display methods

The patent claims a method of organizing product information on a website, which VB Assets argues Amazon infringes upon by utilizing similar display and transaction methods.


What are the core allegations?

  1. Patent Infringement: Amazon's e-commerce platform uses patented methods for product display and transaction management.
  2. Willful Infringement: Proposal by VB Assets that Amazon intentionally infringed the patent.
  3. Damages: VB Assets seeks monetary compensation, including damages for patent infringement and injunctive relief to stop Amazon from further infringement.

What defenses has Amazon raised?

  • Patent Invalidity: Amazon challenges the validity of VB Assets’ patent, alleging prior art that predates the patent issuance, such as earlier online retail interfaces.
  • Non-Infringement: Amazon claims its technology does not infringe on the patent claims.
  • Patent Patentable Subject Matter: Amazon argues the patent claims are too abstract and fail the patent eligibility criteria under 35 U.S.C. § 101.

How have the courts evaluated the case?

  • The court conducted a claim construction hearing in 2021, clarifying the scope of key patent claims.
  • A motion for summary judgment from Amazon on patent invalidity is pending, with some prior evidence suggesting pre-existing online interfaces.
  • The court has not yet issued a final decision on patent validity or infringement.

What are the implications for the industry?

  • The case exemplifies the ongoing patent disputes in the e-commerce sector over display and transaction technologies.
  • A favorable judgment for VB Assets could reinforce patent protections for interface design, impacting platform development.
  • A ruling favoring Amazon could bolster defenses against patent infringement claims based on UI and transaction methods, potentially limiting patent enforcement in similar cases.

Key takeaways

  • The case hinges on patent validity and whether Amazon’s technology infringes the patent rights due to similarity in online transaction and display methods.
  • Amazon's challenge to patent validity relies on prior art, with court proceedings ongoing.
  • The outcome could influence patent enforcement strategies and interface design standards in e-commerce.

Top FAQs

1. Will the case set a precedent for online transaction patents?
It depends on the court ruling. A ruling affirming the patent's validity could strengthen patent protections for interface methods. Conversely, invalidation might limit claims based on abstract UI concepts.

2. What is the main legal challenge for VB Assets?
Proving the patent’s validity amid prior art references and demonstrating infringement in a highly dynamic online environment.

3. How long might the case last?
Based on past patent cases, a final judgment could take 1-2 years post-decision on key motions, with potential for appeals extending resolution further.

4. Are there other similar cases?
Yes, Samsung v. Apple and other patent disputes highlight the contentious nature of UI and transaction patent rights in tech.

5. How does this case impact Amazon’s broader patent strategy?
Amazon may increase patent filings for proprietary interface features to defend against future infringement claims, while also engaging in patent licensing negotiations.


References

  1. Docket entries on PACER, 1:19-cv-01410, District of Delaware.
  2. Patent: U.S. Patent No. 9,832,941, issued Nov 7, 2017.
  3. Federal Circuit decisions on patent eligibility standards.
  4. Industry analysis on e-commerce patent litigation trends.

Note: The case remains unresolved as of 2023, with ongoing motions. The precise impact depends on future rulings.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.